Systemic Score Predicts Still's Disease Severe Complications A multinational study of adults with Still's disease found that calculating their systemic score at baseline significantly predicted the patients risk for life-threatening outcomes. https://t.co/YB7EcWFruE https://t.co/Vcql5tZHOk

Research on SGLT2 inhibitors in #gout is needed. They have been shown to reduce uric acid & gout flares, and may be uricosuric or be antiinflammatory. Also decreased incident gout (by half) among at-risk patients with type 2 diabetes (HR 0.54) https://t.co/CGG9aFsgoD https://t.co/5O2f3MFL8C

Korean claims study of #RA & pregnancy (& adverse preg outcomes (APO), shows MTX or LEF use w/in 3 mos of conception assoc w/ incr. in APOs (aOR 2.14-.68). In 5728 preg: 1152 APOs, HCQ most commonly used, DMARD use decreased during preg. https://t.co/7UBsNdpRgx https://t.co/cY1N73FG8Q

Korean biologics registry study 526 Ank Spondylitis pts on TNFi > 1yr and tapered; 24.1% experienced flares. Predictors of flare included B27+, inflammatory LBP, psoriasis, SpA Fam Hx, DM, ≥50% TNFi tapering, Dz activity (ASDAS-CRP, BASFI) at tapering https://t.co/jjyMX3borT https://t.co/u0lbtfCyz1

GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/MOyfdCJywC

Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw

Secondary Sjogren’s Ups Rheumatoid Arthritis Severity A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment. https://t.co/4dcackIe4S https://t.co/5VZ9I7r29F

Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds: - SLE (RR 1.73) - Scleroderma (1.65) - Psoriasis (1.48) - Vasculitis (1.48) - RA (1.4) - UC &CD (~1.42) - Sarcoid (1.42) https://t.co/RrXaaqz3Aw https://t.co/9dGoGRCBYu

2023 EULAR Psoriatic Arthritis Recommendations EULAR has updated its treatment recommendations— The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies. https://t.co/ja4g5I9emg https://t.co/9pxeup5ACg

Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. You won’t want to miss it! https://t.co/86wJ323nwT https://t.co/WX1wBJ3yoo

Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. Sponsored by Novartis Pharmaceutical Corporation. https://t.co/b9PNCOiL7q https://t.co/7n5DwdmaIQ

Higher Rates of Childlessness in Rheumatic Diseases A Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women. https://t.co/pBoSBGGMxA https://t.co/j8RGT9qrKL